Angina Pectoris

Also known as: Ischemic chest pain / Anginal syndrome / Stenocardia / Angina equivalent / Anginal pain / Anginal discomfort / Angina syndrome / Ischaemic chest pain / Angina

DrugDrug NameDrug Description
DB00335AtenololAtenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize.[A178429] Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label]
DB01020Isosorbide MononitrateIsosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur. Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive. Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium. The adverse reactions which follow have been reported in studies with isosorbide mononitrate: Very common. Up to 30% of patients experience headaches and 2-3 % of patients withdraw treatment for this reason, but the incidence reduces rapidly as treatment continues . Common. 6% of patients experience tiredness, sleep disturbances, and gastrointestinal disturbances. 4-5% of patients experience hypotension, 2.5% experience poor appetite, and 1% experience nausea. Patients experience similar adverse effects as they would for all nitrate treatments and their incidence is most common early in treatment. These symptoms generally disappear during long-term treatment. Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn
DB00883Isosorbide dinitrateA vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
DB00264MetoprololMetoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
DB01203NadololA non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]
DB00727NitroglycerinA volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium.
DB00960PindololA moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
DB00571PropranololA widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety.
DrugDrug NameTargetType
DB00335AtenololBeta-1 adrenergic receptortarget
DB00335AtenololBeta-2 adrenergic receptortarget
DB00335AtenololCytochrome P450 2D6enzyme
DB00335AtenololBile salt export pumptransporter
DB00335AtenololSerum albumincarrier
DB01020Isosorbide MononitrateCytochrome P450 3A4enzyme
DB01020Isosorbide MononitrateGuanylate cyclase soluble subunit alpha-2target
DB00883Isosorbide dinitrateAtrial natriuretic peptide receptor 1target
DB00883Isosorbide dinitrateCytochrome P450 3A4enzyme
DB00883Isosorbide dinitrateCytochrome P450 2E1enzyme
DB00264MetoprololBeta-1 adrenergic receptortarget
DB00264MetoprololCytochrome P450 2D6enzyme
DB00264MetoprololBeta-2 adrenergic receptortarget
DB00264MetoprololSolute carrier family 22 member 2transporter
DB00264MetoprololMultidrug resistance protein 1transporter
DB00264MetoprololSerum albumincarrier
DB00264MetoprololCytochrome P450 3A4enzyme
DB01203NadololBeta-1 adrenergic receptortarget
DB01203NadololBeta-2 adrenergic receptortarget
DB01203NadololMultidrug resistance protein 1transporter
DB01203NadololCytochrome P450 2D6enzyme
DB00727NitroglycerinAtrial natriuretic peptide receptor 1target
DB00727NitroglycerinAldehyde dehydrogenase, mitochondrialenzyme
DB00960PindololBeta-1 adrenergic receptortarget
DB00960PindololBeta-2 adrenergic receptortarget
DB00960Pindolol5-hydroxytryptamine receptor 1Atarget
DB00960Pindolol5-hydroxytryptamine receptor 1Btarget
DB00960PindololCytochrome P450 2D6enzyme
DB00960PindololBeta-3 adrenergic receptortarget
DB00571PropranololBeta-1 adrenergic receptortarget
DB00571PropranololBeta-2 adrenergic receptortarget
DB00571PropranololBeta-3 adrenergic receptortarget
DB00571Propranolol5-hydroxytryptamine receptor 1Atarget
DB00571Propranolol5-hydroxytryptamine receptor 1Btarget
DB00571PropranololCytochrome P450 1A2enzyme
DB00571PropranololCytochrome P450 2D6enzyme
DB00571PropranololAlpha-1-acid glycoprotein 1carrier
DB00571PropranololCytochrome P450 2C19enzyme
DB00571PropranololCytochrome P450 3A4enzyme
DB00571PropranololCytochrome P450 3A5enzyme
DB00571PropranololCytochrome P450 3A7enzyme
DB00571PropranololSolute carrier family 22 member 2transporter
DB00571PropranololMultidrug resistance protein 1transporter
DB00571PropranololCytochrome P450 1A1enzyme
DB00571PropranololAmine oxidase [flavin-containing] Aenzyme
DrugDrug NamePhaseStatusCount
DB00640Adenosine1 / 2Completed1
DB09106Hydroxyethyl Starch2Completed1
DB11816Omecamtiv Mecarbil2Completed1
DB00945Acetylsalicylic acid3Completed1
DB14304Panax notoginseng root3Completed1
DB00945Acetylsalicylic acid4Completed1
DB00126Ascorbic acid4Recruiting1
DB00758Clopidogrel4Active Not Recruiting1
DB00159Icosapent4Not Yet Recruiting1
DB00727Nitroglycerin4Not Yet Recruiting1
DB06209Prasugrel4Active Not Recruiting1
DB01098Rosuvastatin4Not Yet Recruiting1
DB09153Sodium chloride4Recruiting1
DB00624Testosterone4Unknown Status1
DB00381AmlodipineNot AvailableCompleted1
DB06692AprotininNot AvailableCompleted1
DB01076AtorvastatinNot AvailableCompleted1
DB00796Candesartan cilexetilNot AvailableTerminated1
DB00758ClopidogrelNot AvailableRecruiting1
DB00966TelmisartanNot AvailableTerminated1